Short communication: High effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients

AIDS Research and Human Retroviruses

Volumn 27, Issue 7, 2011, Pages 713-717

  Santos, José R ^a,b   Llibre, Josep M ^a,b   Domingo, Pere ^b   Imaz, Arkaitz ^b,c   Ferrer, Elena ^d   Podzamczer, Daniel ^d   Bravo, Isabel ^a   Ribera, Esteban ^b,c   Videla, Sebastià ^a   Clotet, Bonaventura ^a,e  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e IrsiCaixa Foundation   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; EXANTHEMA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; PYRROLIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79959838785     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0283     Document Type: Article

References (21)

1. Hicks Ch, Cahn P, Cooper D, et al.: Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-475. (Pubitemid 44142769)
2. Madruga JV, Cahn P, Grinsztejn B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38. (Pubitemid 47017466)
3. Lazzarin A, Campbell T, Clotet B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48. (Pubitemid 47017467)
4. Clotet B, Bellos N, Molina JM, et al.: Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178. (Pubitemid 46541620)
5. Steigbigel RT, Cooper D, Kumar PN, et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-354.
6. Gulick RM, Lalezari J, Goodrich J, et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-1441.
7. European AIDS Clinical Society: Clinical Management and Treatment of HIV infected adults in Europe. EACS guidelines, version 5.0, November 2009. Available at http://www.europeanaidsclinicalsociety.org/guidelines.asp.
8. Llibre JM, Schapiro JM, and Clotet B: Clinical Implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. CID 2010; 50:872-881.
9. Yazdanpanah Y, Fagard C, Descamps D, et al.: High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: Results of the ANRS 139 TRIO trial. Proceedings of the XVII International AIDS Conference, 3-8 August 2008, Mexico. Abstract THAB0406.
10. Towner W, Lalezari J, Sension MG, et al.: Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: Analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr 2010;53:614-618.
11. Nozza S, Galli L, Visco F, et al.: Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 2010;24:924-928.
12. Imaz A, Del Saz SV, Ribas MA, et al.: Raltegravir, etravirine, and ritonavir-boosted darunavir: A safe and successful rescue regimen for multidrug-resistant HIV-1 Infection. J Ac-quir Immune Defic Syndr 2009;52:382-386.
13. Division of AIDS table for grading the severity of adult and pediatric adverse events version 1.0, December, 2004; Clarification August 2009. Available at http://rcc.techres.com/Document/safetyandpharmacovigilance/DAIDS-AE- GradingTable-Clarification-August2009-Final.pdf.
14. CJ Cohen, DS Berger, G Blick, et al.: Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS 2009;23:423-426.
15. Katlama C, Haubrich R, Lalezari J, et al.: Efficacy and safety of etravirine in treatment experienced, HIV-1 patients: Pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23:2289-2300.
16. Florence E, De Wit S, Castagna A, et al.: Antiretroviral treatment use and HIV RNA suppression rates for 941 European patients in the etravirine early access programme. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 9-13 November 2008. Poster P36.
17. Hammer SM, Eron JJ, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA Panel. JAMA 2008;300 (5):555-570.
18. Gazzard B, Bernard AJ, Boffito M, et al.: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503. (Pubitemid 44742349)
19. Cahn P, Fourie J, Grinsztejn B, et al.: Efficacy and safety at 48 weeks of once-daily vs twice-daily DRV/r in treatment-experienced HIV-1\+ patients with no DRV resistance-associated mutations: The ODIN Trial. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco 16-19, 2010. Poster 57.
20. McCarthy MC, Suleiman J, Diaz R, et al.: Vicriviroc long-term safety and efficacy: 96-week results from the extension of VICTOR-E1 study. 49th ICAAC, San Francisco, California, September 12-15, 2009. Abtsract H-923.
21. Cahn P, Molina JM, Towner W, et al.: 48 week pooled analysis of the DUET 1 and DUET 2: The impact of baseline characteristics on virologic response to etravirine. XVIIth International AIDS Conference, Mexico, 3-8 August 2008. Abstract TUPE0047.